Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Aclaris Therapeutics, Inc. | 3,159,165 | reported | 27 Jun 2019 | tx 2−699,475 |
| Acutus Medical, Inc. | 1,889,509 | reported | 30 Jun 2022 | tx 2+3,779,018 |
| Q32 Bio Inc. | 1,766,106 | reported | 24 Dec 2019 | tx 4+46,740−350,000 |
| DA32 Life Science Tech Acquisition Corp. | 1,600,000 | reported | 30 Jul 2021 | tx 2+2,250,000 |
| Revolution Medicines, Inc. | 1,297,589 | reported | 18 Feb 2020 | tx 6+2,096,384−1,496,384 |
| GYRE THERAPEUTICS, INC. | 1,113,222 | reported | 08 Mar 2018 | tx 5−71,778 |
| AVADEL PHARMACEUTICALS PLC | 952,265 | reported | 25 Jun 2018 | tx 1−114,034 |
| XERIS PHARMACEUTICALS INC | 863,711 | reported | 07 Feb 2019 | tx 3−14,807 |
| Cabaletta Bio, Inc. | 700,000 | reported | 29 Oct 2019 | tx 5+1,628,506−1,392,758 |
| Oncology Institute, Inc. | 58,945 | reported | 12 Nov 2021 | tx 11+4,612,696−808,000 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 18 Jun 2025 | GRANT_AWARD | Nuvalent, Inc. | 2,647 | 0.00 USD | |
| 18 Jun 2025 | GRANT_AWARD | Nuvalent, Inc. | 2,647 | 0.00 USD | |
| 18 Jun 2025 | GRANT_AWARD | Nuvalent, Inc. | 4,147 | 0.00 USD | deriv |
| 18 Jun 2025 | GRANT_AWARD | Nuvalent, Inc. | 4,147 | 0.00 USD | deriv |
| 13 May 2025 | GRANT_AWARD | Larimar Therapeutics, Inc. | 19,000 | 0.00 USD | deriv |
| 14 Apr 2025 | GRANT_AWARD | BiomX Inc. | 17,600 | 0.00 USD | deriv |
| 27 Feb 2025 | EXERCISE | BiomX Inc. | 353,249 | 0.93 USD | |
| 27 Feb 2025 | EXERCISE | BiomX Inc. | 353,249 | 0.93 USD | |
| 27 Feb 2025 | EXERCISE | BiomX Inc. | 1,611,863 | — | deriv |
| 27 Feb 2025 | EXERCISE | BiomX Inc. | 1,611,863 | — | deriv |
| 27 Feb 2025 | GRANT_AWARD | BiomX Inc. | 1,258,614 | — | deriv |
| 27 Feb 2025 | GRANT_AWARD | BiomX Inc. | 1,258,614 | — | deriv |
| 15 Jun 2023 | GRANT_AWARD | Nuvalent, Inc. | 15,000 | 0.00 USD | deriv |
| 15 Jun 2023 | GRANT_AWARD | Nuvalent, Inc. | 15,000 | 0.00 USD | deriv |
| 09 May 2023 | GRANT_AWARD | Larimar Therapeutics, Inc. | 8,300 | 0.00 USD | deriv |
| 30 Jun 2022 | GRANT_AWARD | Acutus Medical, Inc. | 1,889,509 | — | deriv |
| 30 Jun 2022 | GRANT_AWARD | Acutus Medical, Inc. | 1,889,509 | — | deriv |
| 16 Jun 2022 | GRANT_AWARD | Nuvalent, Inc. | 20,000 | 0.00 USD | deriv |
| 16 Jun 2022 | GRANT_AWARD | Nuvalent, Inc. | 20,000 | 0.00 USD | deriv |
| 12 Nov 2021 | CONVERSION | Oncology Institute, Inc. | 40 | — | |
| 12 Nov 2021 | CONVERSION | Oncology Institute, Inc. | 85,113 | — | |
| 12 Nov 2021 | OTHER | Oncology Institute, Inc. | 625,000 | — | deriv |
| 12 Nov 2021 | OTHER | Oncology Institute, Inc. | 3,177,543 | — | deriv |
| 12 Nov 2021 | CONVERSION | Oncology Institute, Inc. | 40 | 0.00 USD | deriv |
| 12 Nov 2021 | OTHER | Oncology Institute, Inc. | 14,887 | 0.00 USD | deriv |
1 purchase reported after at least 12 months of silence — most recent on 30 Jul 2021.